# ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma

> **NCT05116683** · PHASE2 · TERMINATED · sponsor: **Benjamin Izar** · enrollment: 4 (actual)

## Conditions studied

- Leiomyosarcoma
- Liposarcoma

## Interventions

- **DRUG:** ATX-101

## Key facts

- **NCT ID:** NCT05116683
- **Lead sponsor:** Benjamin Izar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-11
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-10-27
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study terminated by PI
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116683, "ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05116683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*